A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease
摘要:
Alzheimer's disease (AD) has been treated with acetylcholinesterase (AChE) inhibitors such as donepezil. However, the clinical usefulness of AChE inhibitors is limited mainly due to their adverse peripheral effects. Depression seen in AD patients has been treated with serotonin transporter (SERT) inhibitors. We considered that combining SERT and AChE inhibition could improve the clinical usefulness of AChE inhibitors. In a previous paper, we found a potential dual inhibitor, 1, of AChE (IC50 = 101 nM) and SERT (IC50 = 42 nM), but its AChE inhibition activity was less than donepezil (IC50 = 10 nM). Here, we report the conformationally restricted (R)-18a considerably enhanced inhibitory activity against AChE (IC50 14 nM) and SERT (IC50 = 6 nM). (C) 2003 Elsevier Ltd. All rights reserved.
Aza-annulation as a versatile approach to the synthesis of non-benzodiazepene compounds for the treatment of sleep disorders
摘要:
The aza-annulation of enamino ester substrates has been demonstrated as an efficient alternative to the syntheses of non-benzodiazepine sleep inducers. Enamino ester substrates derived from aryl, thiophene, and indole functionality were prepared from the corresponding ethyl amines by isothiocyanate formation followed by acid catalyzed cyclization. (C) 1997 Elsevier Science Ltd.
[EN] 3-SUBSTITUTED PYRROLO (2.1-A) ISOQUINOLINE DERIVATIVES<br/>[FR] DERIVES DE LA PYRROLO (2.1-A) ISOQUINOLEINE SUBSTITUES EN 3
申请人:BAYER AG
公开号:WO2003014115A1
公开(公告)日:2003-02-20
The present invention relates to pyrrolo[2.1-a]dihydroisoquinolines which are inhibitors of phosphodiesterase 10a and can be used for combating cancer.
[EN] 3-SUBSTITUTED PYRROLO[2.1-A]ISOQUINOLINE DERIVATIVES<br/>[FR] DERIVES DE 3-PYRROLO[2.1-A]ISOQUINOLEINE SUBSTITUES
申请人:BAYER AG
公开号:WO2003014117A1
公开(公告)日:2003-02-20
The present invention relates to 3-substituted pyrrolo[2.1-a]dihydroisoquinolines which are in-hibitors of phosphodiesterase 10a and can be used for combating cancer.